share_log

HC Wainwright & Co. Reiterates Buy on Keros Therapeutics, Lowers Price Target to $47

Benzinga ·  Dec 13, 2024 19:35  · Ratings

HC Wainwright & Co. analyst Andrew Fein reiterates Keros Therapeutics (NASDAQ:KROS) with a Buy and lowers the price target from $100 to $47.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment